SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myriad Genetics, Inc. - MYGN

NEW YORK, March 15, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Myriad Genetics, Inc. ("Myriad" or the "Company") (NASDAQ: MYGN).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.

The investigation concerns whether Myriad and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On March 12, 2018, post-market, Myriad disclosed that it had received a subpoena from the Department of Health and Human Services, Office of Inspector General, in connection with "an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid." 

On this news, Myriad's share price fell $4.01, or 12.14%, to close at $29.01 on March 13, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 9980

SOURCE Pomerantz LLP